Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q7Z4G1

UPID:
COMD6_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q7Z4G1; A6NF28; B7ZLN0; Q5TBK4

BACKGROUND:
The COMM domain-containing protein 6 is instrumental in controlling the activity of cullin-RING E3 ubiquitin ligase complexes, crucial for protein degradation and signaling. Its ability to down-regulate NF-kappa-B activation and inhibit TNF-induced NFKB1 activation underscores its pivotal role in modulating inflammatory responses.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of COMM domain-containing protein 6 offers a pathway to novel therapeutic interventions. Given its regulatory role in inflammation, targeting this protein could lead to breakthrough treatments for conditions driven by abnormal inflammatory processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.